SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Altimmune, Inc. Securities and Sets a Lead Plaintiff Deadline of October 6, 2025

Core Viewpoint - A class action lawsuit has been initiated against Altimmune, Inc. following disappointing results from its Phase 2b MASH trial of Pemvidutide, leading to a significant drop in the company's stock price [1][3][4]. Company Overview - Altimmune, Inc. is a biopharmaceutical company focused on developing treatments for liver diseases, including MASH [3]. Legal Proceedings - The lawsuit, Dave Collier v. Altimmune, Inc., was filed in the United States District Court for the District of Maryland, targeting all individuals who purchased Altimmune securities between August 10, 2023, and June 25, 2025 [1]. - Investors have until October 6, 2025, to request to be appointed as lead plaintiff in the case [4]. Trial Results - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [3]. - The company had previously set inflated expectations for the trial results, which were not met due to a higher-than-expected placebo response [3]. Stock Performance - Following the announcement of the trial results, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [4].